Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status.

Harwood M, Dunn N, Moore J, Mollee P, Hapgood G.

Leuk Lymphoma. 2020 Mar;61(3):721-727. doi: 10.1080/10428194.2019.1688322. Epub 2019 Nov 14.

PMID:
31724464
2.

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.

Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G.

Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458.

3.

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.

Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY.

Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24.

PMID:
30983008
4.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. No abstract available.

PMID:
30873584
5.

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.

Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2019 Apr;60(4):904-911. doi: 10.1080/10428194.2018.1516873. Epub 2018 Dec 14.

PMID:
30547695
6.

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Blombery P, Thompson E, Ryland GL, Joyce R, Byrne DJ, Khoo C, Lade S, Hertzberg M, Hapgood G, Marlton P, Deva A, Lindeman G, Fox S, Westerman D, Prince M.

Oncotarget. 2018 Nov 16;9(90):36126-36136. doi: 10.18632/oncotarget.26308. eCollection 2018 Nov 16.

7.

Relative survival of patients with lymphoma in Queensland according to histological subtype.

Wright F, Hapgood G, Loganathan A, Dunn N, Philpot S, Moore J, Mollee P.

Med J Aust. 2018 Aug 20;209(4):166-172. Epub 2018 Aug 13.

PMID:
30092750
8.

Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.

Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY.

Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. No abstract available.

PMID:
29676487
9.

Defining the clonality of peripheral T cell lymphomas using RNA-seq.

Brown SD, Hapgood G, Steidl C, Weng AP, Savage KJ, Holt RA.

Bioinformatics. 2017 Apr 15;33(8):1111-1115. doi: 10.1093/bioinformatics/btw810.

10.

Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience.

Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ.

Br J Haematol. 2017 Jan;176(2):234-240. doi: 10.1111/bjh.14404. Epub 2016 Oct 21.

PMID:
27766622
11.

Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.

Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack GW, Parsons C, Morris J, Pickles T, Connors JM, Savage KJ.

J Clin Oncol. 2016 Jul 20;34(21):2493-500. doi: 10.1200/JCO.2015.65.4194. Epub 2016 Jun 6.

PMID:
27269949
12.

X. Challenges and future directions in peripheral T-cell lymphoma.

Hapgood G, Savage KJ.

Hematol Oncol. 2015 Jun;33 Suppl 1:56-61. doi: 10.1002/hon.2218. Review. No abstract available.

PMID:
26062056
13.

Erythropoiesis is not equally suppressed in transfused males and females with β-thalassemia major: are there clinical implications?

Hapgood G, Walsh T, Cukierman R, Paul E, Cheng K, Bowden DK.

Haematologica. 2015 Aug;100(8):e292-4. doi: 10.3324/haematol.2014.118216. Epub 2015 Apr 24. No abstract available.

14.

The biology and management of systemic anaplastic large cell lymphoma.

Hapgood G, Savage KJ.

Blood. 2015 Jul 2;126(1):17-25. doi: 10.1182/blood-2014-10-567461. Epub 2015 Apr 13. Review.

PMID:
25869285
15.

Tracing the tiger: population genetics provides valuable insights into the Aedes (Stegomyia) albopictus invasion of the Australasian Region.

Beebe NW, Ambrose L, Hill LA, Davis JB, Hapgood G, Cooper RD, Russell RC, Ritchie SA, Reimer LJ, Lobo NF, Syafruddin D, van den Hurk AF.

PLoS Negl Trop Dis. 2013 Aug 8;7(8):e2361. doi: 10.1371/journal.pntd.0002361. eCollection 2013.

16.

A mysterious case of Dr Cabot.

Hapgood G, Roy S.

Br J Haematol. 2013 Sep;162(6):719. doi: 10.1111/bjh.12471. Epub 2013 Jul 24. No abstract available.

PMID:
23889521
17.

The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.

Hapgood G, Butler J, Malan E, Chunilal S, Tran H.

Thromb Haemost. 2013 Aug;110(2):308-15. doi: 10.1160/TH13-04-0301. Epub 2013 Jun 20.

PMID:
23783268
18.

Immune-mediated cytopenias in human immunodeficiency virus: the first reported case of idiopathic aplastic anaemia successfully treated with immunosuppression.

Hapgood G, Hoy JF, Morrissey CO, Jane SM.

Intern Med J. 2013 Apr;43(4):452-5. doi: 10.1111/imj.12087. Review.

PMID:
23551309
19.

Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation.

Hapgood G, Mooney E, Dinh HV, Gin D, McLean C, Ting SB.

Intern Med J. 2012 Dec;42(12):1355-8. doi: 10.1111/imj.12000.

PMID:
23253001
20.

Rapid identification of Aedes albopictus, Aedes scutellaris, and Aedes aegypti life stages using real-time polymerase chain reaction assays.

Hill LA, Davis JB, Hapgood G, Whelan PI, Smith GA, Ritchie SA, Cooper RD, van den Hurk AF.

Am J Trop Med Hyg. 2008 Dec;79(6):866-75.

PMID:
19052295
21.

Murray Valley encephalitis virus surveillance and control initiatives in Australia. National Arbovirus Advisory Committee of the Communicable Diseases Network Australia.

Spencer JD, Azoulas J, Broom AK, Buick TD, Currie B, Daniels PW, Doggett SL, Hapgood GD, Jarrett PJ, Lindsay MD, Lloyd G, Mackenzie JS, Merianos A, Moran RJ, Ritchie SA, Russell RC, Smith DW, Stenhouse FO, Whelan PI.

Commun Dis Intell Q Rep. 2001 Apr;25(2):33-47. Erratum in: Commun Dis Intell 2001 Aug;25(3):155.

Supplemental Content

Loading ...
Support Center